Sector Gamma AS Makes New $17.01 Million Investment in Eli Lilly And Co (NYSE:LLY)

Sector Gamma AS bought a new position in shares of Eli Lilly And Co (NYSE:LLY) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 152,105 shares of the company’s stock, valued at approximately $17,010,000. Eli Lilly And Co accounts for approximately 2.9% of Sector Gamma AS’s holdings, making the stock its 12th largest position.

A number of other hedge funds also recently made changes to their positions in LLY. Selective Wealth Management Inc. bought a new position in Eli Lilly And Co during the third quarter worth $25,000. Enterprise Trust & Investment Co bought a new position in Eli Lilly And Co during the third quarter worth $27,000. Garrett Wealth Advisory Group LLC bought a new position in Eli Lilly And Co during the third quarter worth $29,000. Candriam Luxembourg S.C.A. boosted its position in shares of Eli Lilly And Co by 47.7% in the third quarter. Candriam Luxembourg S.C.A. now owns 270,304 shares of the company’s stock valued at $30,000 after acquiring an additional 87,250 shares during the period. Finally, Prestige Wealth Management Group LLC bought a new stake in shares of Eli Lilly And Co in the second quarter valued at about $34,000. Hedge funds and other institutional investors own 77.22% of the company’s stock.

In other news, Director Jackson P. Tai acquired 1,861 shares of the stock in a transaction dated Thursday, October 24th. The stock was bought at an average price of $107.49 per share, with a total value of $200,038.89. Following the completion of the purchase, the director now directly owns 56,440 shares of the company’s stock, valued at approximately $6,066,735.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joshua L. Smiley acquired 929 shares of the stock in a transaction dated Friday, October 25th. The stock was purchased at an average cost of $107.59 per share, with a total value of $99,951.11. Following the purchase, the chief financial officer now directly owns 31,524 shares of the company’s stock, valued at $3,391,667.16. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 8,405 shares of company stock valued at $909,004 and have sold 614,373 shares valued at $70,546,895. 0.11% of the stock is currently owned by insiders.

NYSE LLY traded up $0.76 during trading on Friday, hitting $113.53. 2,190,598 shares of the company’s stock were exchanged, compared to its average volume of 7,683,282. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 4.09. The company has a market cap of $106.81 billion, a PE ratio of 20.46, a P/E/G ratio of 1.82 and a beta of 0.16. Eli Lilly And Co has a fifty-two week low of $101.36 and a fifty-two week high of $132.13. The stock’s 50 day moving average price is $110.61 and its two-hundred day moving average price is $112.67.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Wednesday, October 23rd. The company reported $1.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.43 by $0.05. The firm had revenue of $5.48 billion during the quarter, compared to the consensus estimate of $5.50 billion. Eli Lilly And Co had a return on equity of 107.99% and a net margin of 35.10%. The business’s quarterly revenue was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.39 earnings per share. Analysts forecast that Eli Lilly And Co will post 5.78 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a yield of 2.27%. The ex-dividend date is Thursday, November 14th. Eli Lilly And Co’s payout ratio is 46.49%.

A number of equities research analysts have recently issued reports on LLY shares. UBS Group reduced their target price on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research report on Thursday, October 17th. Bank of America assumed coverage on shares of Eli Lilly And Co in a research report on Wednesday, October 16th. They set a “buy” rating and a $133.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $130.03.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: What is the role of the G-20?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply